Loading...

APC anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_APC_030206
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • RM4-5_APC_030206
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100515 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100516 100 µg 84€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  2. Cosgrove J, et al. 2020. Nat Commun. 3.011805556. PubMed
  3. Ying W, et al. 2019. Cell Metab. 29:457. PubMed
  4. McNamara HA, et al. 2020. Cell Host Microbe. 572:28. PubMed
  5. Hirako I, et al. 2016. Nat Commun. 7:13277. PubMed
  6. Zhang LJ, et al. 2019. Immunity. 50:121. PubMed
  7. Suzuki K, et al. 2019. Cell Mol Gastroenterol Hepatol. 8:119. PubMed
  8. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  9. Yu Y, et al. 2022. iScience. 25:105004. PubMed
  10. Fisher E, et al. 2021. Front Immunol. 11:602254. PubMed
  11. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  12. Lee J, et al. 2020. Gut Microbes. 1:. PubMed
  13. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  14. Matsumoto M, et al. 2007. J Immunol . 178:2499. PubMed
  15. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  16. Rodriguez-Manzanet R, et al. 2010. Proc Natl Acad Sci U S A. 107:8706. PubMed
  17. Zhao B, et al. 2020. Nat Commun. 11:908. PubMed
  18. Bhattacharjee S, et al. 2019. Cell Rep. 28:231. PubMed
  19. Pokrovskii M, et al. 2020. EMBO J. 39:e104159. PubMed
  20. Webster HC, et al. 2020. J Immunol Methods. 112702:477. PubMed
  21. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  22. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  23. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  24. Ayasoufi K, et al. 2020. Brain. 3629:143. PubMed
  25. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  26. Huang B, et al. 2020. Cell. 179(5):1160-1176.e24.. PubMed
  27. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  28. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  29. Li Y, et al. 2020. Nat Commun. 11:2781. PubMed
  30. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  31. Shigeta A, et al. 2008. Blood. 112:4915. PubMed
  32. van der Lelie D, et al. 2021. Nat Commun. 12:3105. PubMed
  33. Kang S, et al. 2021. Bio Protoc. 11:e4029. PubMed
  34. Nakajima A, et al. 2014. PLoS One. 9:105904. PubMed
  35. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  36. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  37. Park S, et al. 2013. J Immunol. 190:3480. PubMed
  38. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  39. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  40. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  41. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  42. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  43. Rovira-Clavé X, et al. 2016. J Leukoc Biol. 99: 143 - 152. PubMed
  44. Tsumiyama K, et al. 2013. J Immunol. 191:91. PubMed
  45. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  46. Lin YW, et al. 2022. Mol Med Rep. 26:. PubMed
  47. Moutuou MM, et al. 2020. Methods Mol Biol. 2111:267. PubMed
  48. Lin J, et al. 2021. Nat Commun. 12:5321. PubMed
  49. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  50. Biton J, et al. 2016. J Immunol. 197: 1708 - 1719. PubMed
  51. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  52. Wu S, et al. 2021. Nat Cancer. 2:189. PubMed
  53. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  54. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  55. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  56. Izumi G, et al. 2021. Nat Commun. 12:5029. PubMed
  57. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  58. Xiao u, et al. 2015. J Immunol. 195: 4218 - 4227. PubMed
  59. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  60. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  61. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  62. Zaborsky N, et al. 2010. J Immunol. 184:725. PubMed
  63. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
  64. Liu J, et al. 2021. Front Immunol. 12:733808. PubMed
  65. Ene CI, et al. 2020. Neuro Oncol. 639:22. PubMed
  66. Lee Y, et al. 2012. Nat Immunol. 13:991. PubMed
  67. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  68. van den Berk P, et al. 2020. Cell Rep. 33:108533. PubMed
  69. Schaffert S, et al. 2015. J Immunol. 195: 1470-1479. PubMed
  70. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  71. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  72. Takahashi T, et al. 2017. J Exp Med. 10.1084/jem.20160247. PubMed
  73. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  74. Denzin LK et al. 2017. Immunity. 47(2):310-322 . PubMed
  75. Hartmann W, et al. 2020. Cell Reports. 29(8):2243-2256.e4.. PubMed
  76. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  77. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  78. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  79. Berry G, Waldner H 2013. J Vis Exp. 75: 50389. PubMed
  80. St Clair JR, et al. 2018. Nat Commun. 9:1742. PubMed
  81. Sudo K, et al. 2021. Stem Cell Res. 56:102531. PubMed
  82. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  83. Li C, et al. 2014. J Immunol. 192:1425. PubMed
  84. Zaiss M, et al. 2015. Immunity. 43: 998-1010. PubMed
  85. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  86. Arima Y et al. 2017. eLife. 6 pii: e25517. PubMed
  87. García–Rodríguez S, et al. 2018. Sci Rep. 2.664583333. PubMed
  88. Wen X, et al. 2021. World J Gastroenterol. 27:2834. PubMed
  89. Parigger T, et al. 2021. Int J Mol Sci. 22:. PubMed
  90. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  91. Palaniyandi S, et al. 2013. PLoS One. 8:61841. PubMed
  92. Pastor Arroyo EM, et al. 2022. Clin Sci (Lond). 136:557. PubMed
  93. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
RRID
AB_312718 (BioLegend Cat. No. 100515)
AB_312719 (BioLegend Cat. No. 100516)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 3    Revision Date: 01.29.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account